Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant

被引:32
作者
Prentice, HG [1 ]
Kho, P [1 ]
机构
[1] GLAXO WELLCOME,BECKENHAM,KENT,ENGLAND
关键词
cytomegalovirus; bone marrow transplant; prophylaxis; pre-emptive therapy;
D O I
10.1038/sj.bmt.1700630
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Four clinical strategies are proposed for the management of CMV disease: prophylaxis, suppression, preemptive therapy and treatment. The degree of risk of developing CMV disease and the safety profile of the presently available drugs need to be considered when deciding on the most appropriate approach, We conclude that a prophylactic strategy employing a drug with a safe toxicity profile followed by pre-emptive treatment with an effective antiviral drug for failure of prophylaxis gives the best outcome in allogeneic HLA matched bone marrow transplant recipients.
引用
收藏
页码:135 / 142
页数:8
相关论文
共 27 条
[1]   FOSCARNET FOR TREATMENT OF CYTOMEGALOVIRUS INFECTIONS IN BONE-MARROW TRANSPLANT RECIPIENTS [J].
ASCHAN, J ;
RINGDEN, O ;
LJUNGMAN, P ;
LONNQVIST, B ;
OHLMAN, S .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1992, 24 (02) :143-150
[2]   PROPHYLACTIC USE OF GANCICLOVIR IN ALLOGENEIC BONE-MARROW TRANSPLANTATION - ABSENCE OF CLINICAL CYTOMEGALOVIRUS-INFECTION [J].
ATKINSON, K ;
DOWNS, K ;
GOLENIA, M ;
BIGGS, J ;
MARSHALL, G ;
DODDS, A ;
CONCANNON, A .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 79 (01) :57-62
[3]  
BACIGALUPO A, 1994, BONE MARROW TRANSPL, V13, P783
[4]   CYTOMEGALOVIRUS IMMUNE GLOBULIN AND SERONEGATIVE BLOOD PRODUCTS TO PREVENT PRIMARY CYTOMEGALOVIRUS-INFECTION AFTER MARROW TRANSPLANTATION [J].
BOWDEN, RA ;
SAYERS, M ;
FLOURNOY, N ;
NEWTON, B ;
BANAJI, M ;
THOMAS, ED ;
MEYERS, JD .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (16) :1006-1010
[5]  
CHANG J, 1995, BR J CANC S24, V71, P69
[6]  
CRUMPACKER C, 1988, REV INFECT DIS S3, V10, P538
[7]  
EMMANUEL D, 1988, ANN INTERN MED, V109, P777
[8]   CYTOMEGALO-VIRUS PNEUMONIA - THE USE OF GANCICLOVIR IN MARROW TRANSPLANT RECIPIENTS [J].
ETTINGER, NA ;
SELBY, P ;
POWLES, R ;
MILLIKEN, S ;
GALLAGHER, C ;
JAMESON, B ;
TRYHORN, Y ;
STERN, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 24 (01) :53-62
[9]   GANCICLOVIR PROPHYLAXIS TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC MARROW TRANSPLANT [J].
GOODRICH, JM ;
BOWDEN, RA ;
FISHER, L ;
KELLER, C ;
SCHOCH, G ;
MEYERS, JD .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (03) :173-178
[10]   EARLY TREATMENT WITH GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
GOODRICH, JM ;
MORI, M ;
GLEAVES, CA ;
DUMOND, C ;
CAYS, M ;
EBELING, DF ;
BUHLES, WC ;
DEARMOND, B ;
MEYERS, JD .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (23) :1601-1607